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NLRC5 is a member of the NLR family that acts as a transcriptional activator of MHC 
class I genes. In line with the function of several related NLR proteins in innate immune 
responses, there is, however, also ample evidence that NLRC5 contributes to innate 
and adaptive immune responses beyond the regulation of MHC class I genes. In human 
and murine cells, for example, NLRC5 was proposed to contribute to inflammatory and 
type I interferon responses. The role of NLRC5 in these and other cellular processes is 
hitherto still not well understood and blurred by discrepancies in the reported data. Here, 
we provide a detailed and critical discussion of the available experimental data on the 
emerging biological functions of NLRC5 in innate immune responses in men and mice. 
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution 
to immune responses and cancer.
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inTRODUCTiOn
In the past decades, we witnessed a rapid increase in our knowledge of the molecular details of innate 
and adaptive immune signaling pathways, including the identification of the cognate innate immune 
receptors, their signaling proteins, and the main effector responses of immunity. Several groups 
of pattern-recognition receptors (PRRs) were identified, such as the cytosolic nucleotide-binding 
domain (NBD), leucine-rich containing proteins (NLR), which are evolutionary conserved proteins 
that serve as sentinels for microbes and cellular stress to trigger induction of innate and adaptive 
immunity. NLRs are tripartite domain-containing proteins that emerged as important sensors for 
pathogen-derived microbe-associated molecular patterns (MAMP) and endogenous danger signals 
[danger-associated molecular patterns (DAMPs)] (1). The archetypical domain organization of an 
NLR protein consists of an N-terminal death-fold domain [mostly a pyrin domain or a caspase 
activation and recruitment domain (CARD)], a central ATPase domain of the signal transduction 
ATPases with numerous domains clade {assigned as NACHT domain [from NLP family apoptosis 
inhibitor protein, class II transcriptional activator (CIITA), HET-E, and TEP1]}, and C-terminal 
leucine-rich repeats (LRR) of various lengths. Notably, mammalian NLRs are close relatives of 
immune proteins found in plants that act as sensors for pathogen-expressed effector proteins (2). In 
the human genome, at least 22 NLRs and in the mouse genome 34 such proteins are encoded, and 
many of these still are poorly characterized. According to our view, the mammalian NLR proteins 
can be subdivided in three functional classes: (I) NLRs that convert microbial sensing to transcrip-
tional reprograming in the host cell, resulting in pro-inflammatory responses and expression of 
bactericidal activities. This is exemplified by NOD1 and NOD2 that are prototypic PRRs (3). (II) 
NLRs that induce formation of a multiprotein complex which was named “inflammasome” that in 
turn recruits and activates the zymogen pro-caspase-1, resulting in caspase-1-mediated processing of 
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the cytokines IL-1β and IL-18 and the induction of pyroptotic cell 
death (examples being NLRP3 and NLRP1) (4, 5). (III) NLRs that 
can translocate into the nucleus and act as transcriptional trans-
activators. The most prominent member of this latter family is the 
CIITA. This protein is essential to drive transcription of major 
histocompatibility complex class II (MHC II) genes by acting as 
a transactivator on MHC II promoter region where it binds to 
indirectly, by interaction with an accessory DNA-binding protein 
complex, the MHC enhanceosome (6). Recently, the NLR protein 
NLRC5 was shown to have a similar function in the regulation of 
MHC class I genes (7–11). Taken together, this nicely exemplifies 
that NLRs contribute to diverse biological functions (12). Here, 
we focus on the NLRC5 protein and our current understanding 
of its biological functions.
NLRC5 was first cloned and characterized in 2010, indepen-
dently by five groups (7, 13–16). It is meanwhile well established 
that NLRC5 shuttles to the nucleus where it can induce the 
transcription of MHC class I genes, in most, albeit not all, cell 
types (17–19). MHC molecules present peptide antigens to T cells 
of the adaptive immune repertoire that interact with MHC–pep-
tide complexes with their cognate T cell receptors. MHC class 
I molecules thereby present cytosolic-derived peptides to CD8+ 
cytotoxic T lymphocytes (CTL), whereas MHC II molecules 
present vesicular-derived peptides to CD4+ T helper cells. NLRC5 
seems to act in a similar manner as CIITA, and its activity is 
regulated mainly at the transcriptional level. Indeed, it was shown 
that expression levels of NLRC5 and MHC class I genes correlate 
in mouse and human cell lines and tissue (7, 9, 10). Many cancer 
entities show reduced or absent MHC I expression, and this is 
discussed as an important event to circumvent CTL-mediated 
antitumor immune responses. As NLRC5 regulates MHC class I 
expression, it might be relevant in the malignant transformation 
process and could eventually be used as intervention to enhance 
antitumor immunity (20–22). Indeed, induced expression of 
NLRC5 was recently correlated with enhanced immunogenicity 
and reduced tumor progression in a mouse model of melanoma 
(23).
Interestingly, although NLRC5 shares sequence homology to 
CIITA, it possesses a rather atypical N-terminal domain, which is 
completely distinct from the CIITA N-terminal domain and that 
of other NLRs. Furthermore, NLRC5 has the longest LRR domain 
of all human NLR proteins (16, 24, 25) (Figure 1). This might 
suggest that NLRC5 has further functions in human cells, and 
indeed, most of the initial reports on NLRC5 did not reveal its 
important function in antigen presentation, but rather suggested 
that NLRC5 contributes to cell-autonomous immune responses 
(13–16).
Here, we provide a detailed discussion of the available data on 
the functions of NLRC5 with a strong focus on its roles beyond 
the well-established and accepted function in regulating MHC 
class I gene expression (Figure 2).
nLRC5 FUnCTiOnS BeYOnD MHC 
ReGULATiOn
Although there is significant progress in understanding the 
structure, the expression, and the transactivating function of 
NLRC5 in the context of MHC class I gene expression, reports 
about cytoplasmic functions and possible roles of NLRC5 in 
innate immune responses remain somewhat controversial and 
unresolved. Innate immune responses, including inflammatory 
cytokine production, are triggered by MAMPs or DAMPs and 
mainly are mediated via pro-inflammatory signal transduc-
tion pathways, inflammasome activation, or type I interferon 
responses. In the following sections, we discuss the reported 
functions of NLRC5 in these pathways.
PRO-inFLAMMATORY ReSPOnSeS
Since the discovery of NLRC5, there are multiple reports on 
functions of NLRC5 in the regulation of signal transduction 
pathways and pro-inflammatory cytokine production. Based on 
some early reports from 2010, describing that NLRC5 can inhibit 
nuclear factor kappa B (NF-κB) signaling (13, 14), the view of 
NLRC5 as a negative regulator of inflammatory responses has 
been established. Using reporter assays, it was shown that NLRC5 
decreased NF-κB, interferon-sensitive response element (ISRE), 
and activator protein 1 signaling, and silencing of NLRC5 in the 
murine macrophage cell line RAW264.7 resulted in increased 
IL-6, TNF, RANTES (CXCL5), and IL-1β secretion (13, 14) and 
at the same time decreased secretion of the anti-inflammatory 
cytokine IL-10 (13). This inhibitory role of NLRC5 was explained 
by direct interaction between NLRC5 and IκB kinase alpha/beta 
(IKKα/β) that prevents the binding of NEMO (IKKγ) to the 
IKK subunits and inhibits their autophosphorylation and kinase 
activity (14). More recently, the same authors modeled NF-κB 
regulation by NLRC5 and revealed that reversible ubiquitination 
of NLRC5 has an important regulatory role in the activation of 
NF-κB signaling (26). They showed that following lipopolysac-
charide (LPS) treatment, the E3 ligases TNF receptor-associated 
factors 2/6 (TRAF2/6) mediate NLRC5 ubiquitination on 
Lys1178. This K63-linked ubiquitination leads to the degrada-
tion of NLRC5 that frees IKKα/β complex and activates NF-κB 
pathway (26).
To determine the in  vivo function of NLRC5, Kumar et  al. 
generated NLRC5-deficient C57BL/6 mice by replacing exon 4 
of Nlrc5 with a neomycin-resistance gene cassette (27). However, 
bone marrow-derived dendritic cells (BMDCs) generated from 
wild-type and their Nlrc5−/− mice showed no differences in IL-6 
and TNF pro-inflammatory cytokine production in response to 
LPS treatment or Listeria monocytogenes infection, questioning 
a physiological role of NLRC5 in pro-inflammatory responses in 
this cell type (27). Yao et al. generated another Nlrc5−/− mouse line 
in the C57BL/6 background, replacing exons 1–4 to a neomycin-
resistant gene cassette (11). Consistent with the results from 
Kumar et al., they found that the expression of NF-κB-dependent 
genes did not change in BMDMs of NLRC5-deficient mice upon 
LPS treatment or L. monocytogenes infection (11). Similar results 
were obtained by Robbins et al. using C57BL/6 mice deficient in 
exons 3 and 4 of Nlrc5 that encode a portion of the N-terminal 
domain and the entire NBD of NLRC5. They reported that, fol-
lowing LPS activation, cytokine levels of IL-6, TNF, and IL-1β 
were generally similar between WT and Nlrc5−/− BMDMs and 
peritoneal macrophages (28).
FiGURe 1 | Schematic representation of the human nLRC5 protein structure and domain organization. uCARD, untypical caspase activation and 
recruitment domain (CARD); this domain shows only low sequence similarities to canonical CARD domains. A nuclear localization signal is located in this region. 
NACHT domain, involved in the nucleotide bindings and presumable important for oligomerization and activation of NLRC5. WA and WB are Walker A and Walker B 
motifs, respectively. The WA motif is responsible for nucleotide triphosphate binding; WB motif is responsible for nucleotide triphosphate hydrolysis. WH, winged 
helix domain. SH, superhelical domain, contains eight α-helices, function unknown. LRR, leucine-rich repeat, protein–protein interaction domain, responsible for 
ligand binding in other pattern-recognition receptors.
3
Benko˝ et al. NLRC5 Functions
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 150
In 2012, Tong et  al. generated a different NLRC5-deficient 
mouse line by deleting exon 8 of NLRC5 (29). This exon codes the 
functional domain of NLRC5 that inhibits NF-κB signaling (14). 
In agreement with the Kumar group, they found no differences in 
IL-6, TNFα, and IL-12 secretion between Nlrc5−/− and WT BMDCs 
stimulated with LPS (29). By contrast, when using embryonic 
fibroblasts (MEFs) derived from their Nlrc5−/− mice, they found 
enhanced IKK phosphorylation and NF-κB activation, supporting 
a negative effect of NLRC5 on the IKK pathway. Furthermore, they 
measured elevated mRNA levels of IL-6, TNF, and IL-1β in MEFs 
and peritoneal macrophages of Nlrc5−/− mice upon LPS activation 
(29). Interestingly, they found that NLRC5 deletion enhanced 
IL-6 expression in both MEFs and macrophages, but increased 
production of TNF was only observed in NLRC5-deficient MEFs 
but not in macrophages (29). Unfortunately, from the work, it 
is unclear what mouse background was used, impairing further 
interpretation of these results (29). An inhibitory role of NLRC5 
on inflammatory cytokine production is further supported by 
work from Li et al. who demonstrated that silencing of NLRC5 
in murine RAW264.7 macrophages results in increased IL-6 and 
TNF secretion after LPS activation (30).
Possible explanations for the different reported roles of 
NLRC5 in peritoneal macrophages, BMDMs, BMDCs, and MEFs 
might be the differential expression levels of NLRC5 in these cell 
types, the different availability of accessory proteins for NLRC5 
function, and/or the different regulation of cytokine expression 
in these cells, as exemplified by TNF expression (31). A recent 
paper suggests that ubiquitination of NLRC5, which is different in 
these cell types such as murine peritoneal macrophages, BMMs, 
and BMDCs (26) may explain at least in part these discrepancies.
Taken together, NLRC5 is unlikely a pivotal regulator of pro-
inflammatory responses under physiological conditions; how-
ever, available data strongly suggest that NLRC5 can affect the 
NF-κB pathway, in certain cell types. Interestingly, this function 
of NLRC5 might even be evolutionary conserved as a mutation 
in the promoter region of the NLRC5 homolog in chicken was 
associated with changes in NF-κB responses toward Salmonella 
infection (32) (Figure 2A).
Further research is needed to address and validate indepen-
dently these points and to establish a function of NLRC5 in 
animal models or provide indications for correlation with human 
diseases.
inFLAMMASOMe ACTivATiOn
IL-1β and IL-18 are key inflammatory cytokines. These are pro-
duced in the cell as zymogens that are processed by caspase-1. 
The activation of caspase-1 is mediated by a fibril complex of the 
adaptor protein ASC that is nucleated upon homomeric complex 
formation of NLRP proteins, most importantly NLRP3. These 
NLRs are activated by multiple MAMPs and DAMPs in a still 
not understood manner involving changes in ion flux and redox 
potential [reviewed in Ref. (4, 5)].
As some of the above discussed studies also reported changes 
in IL-1β secretion, it is tempting to speculate that NLRC5 affects 
the function of inflammasomes or might be able to form an 
NLRC5-containing inflammasome.
While Tong et al. and Kumar et al. did not observe any differ-
ences in IL-1β secretion between Nlrc5−/− and WT peritoneal mac-
rophages (27, 29), others have shown that NLRC5 contributes to 
NLRP3 inflammasome activation and inflammasome- dependent 
IL-1β secretion in vitro in response to a variety of NLRP3 stimu-
lators. Short hairpin RNA (shRNA) and small-interfering RNA 
(siRNA) duplexes used to silence NLRC5 in human myeloid 
THP-1 cells and human primary monocytes significantly reduced 
the secretion of IL-1β in response to Escherichia coli infection 
compared to control cells due to reduced caspase-1 activation and 
IL-1β maturation (33). Nevertheless, there were no changes in 
the expression of NLRP3, apoptosis-associated speck-like protein 
(ASC), and pro-IL-1β mRNA suggesting that not the priming 
step but the inflammasome activation requires the presence of 
NLRC5. Using various infection models, it was found that NLRC5 
is required for inflammasome activation by bacterial PAMPs and 
crystals, but not pore-forming toxins (33). Furthermore, co-
immunoprecipitation studies showed that ectopically expressed 
NLRC5 exclusively associated with NLRP3 through the NLRC5-
NBD domain (33). Albeit this is an interesting finding, we would 
like to note that, according to the experience of others and the 
authors (34), NBD domains of NLRs are prone to interact with 
each other resulting in eventual unphysiological complexes.
In consistence with these results, Yao and co-workers 
reported that reduced caspase-1 activation and IL-1β produc-
tion was detected in BMDMs derived from their Nlrc5−/− mice 
upon stimulation with different NLRP3 inflammasome agonists 
such as monosodium urate crystals, the adjuvant alum, and LPS 
FiGURe 2 | Schematic representation of the proposed cellular functions of cellular nLRC5. (A) Several studies suggest a contribution of NLRC5 to the 
nuclear factor kappa B (NF-κB) pathway. This might involve specific ubiquitination of NLRC5. A direct interaction between the IKKα/β and NLRC5 resulting in IKKα/β, 
which is unable to bind to NEMO (IKKγ) as well as reduced autophosphorylation and kinase activity was reported. Following lipopolysaccharide treatment, the TNF 
receptor-associated factors 2/6 (TRAF2/6) mediate NLRC5 ubiquitination. This leads to the degradation of NLRC5 that consequently frees IKKα/β complex and 
activates NF-κB pathway. (B) Possible role of NLRC5 in controlling inflammasome activation. The molecular mechanisms how this is achieved remains elusive. 
NLRC5 might affect priming by the regulation of NF-κB responses or might directly interfere with inflammasome activation. However, available data suggest that 
NLRC5 is more likely involved in the complex forming step of the inflammasome activation. (C) In antiviral responses, some studies suggest that NLRC5 interacts 
with retinoic acid-inducible gene I (RIG-I) and MAVS and might be able to enhance type I interferon responses. However, also contradicting data, suggesting a role 
of NLRC5 I inhibiting type I interferon responses has been presented. Several studies showed that in the absence of NLRC5, the IFNβ response is significantly 
weaker compared to the level observed when NLRC5 interacts with RIG-I and MAVS. (D) Finally, recent works suggest that NLRC5 can be linked to tumorigeneses 
via multiple pathways, such as β-catenin, TGF-β, and Akt, thereby resulting in changed cell proliferation and extracellular matrix deposition. However, these functions 
await validation at present. It should be mentioned that most of the depicted functions await further clarification (see main text for discussion).
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plus ATP (11). In vivo studies showed that NLRC5 contributed 
to L. monocytogenes-induced IL-1β secretion, and decreased 
neutrophil recruitment and bacterial clearance in the spleens 
and livers of infected Nlrc5−/− mice (11). However, no changes 
in pro-IL-1β mRNA were observed in this study, suggesting 
that NLRC5 might directly regulate the activation of the NLRP3 
inflammasome.
In a model system, human rhinovirus (HRV)-induced IL-1β 
expression and caspase-1 activation were monitored in human 
primary epithelial cells, targeted with NLRC5-specific shRNA. 
Using Förster resonance energy transfer, the authors showed that 
following HRV infection, NLRP3 was associated with NLRC5 in 
primary bronchial cells. Furthermore, transfection of the viral 
2B protein, a pore-forming toxin from the virus that enhances 
Ca2+ release from the stores, induced translocation of NLRC5 
and NLRP3 from the cytoplasm to the Golgi apparatus to 
cooperatively sense intracellular Ca2+ fluxes and trigger IL-1β 
secretion (35).
Although these independent reports suggest that NLRC5 
may affect NLRP3 inflammasome pathways in certain settings 
(Figure 2B), it should however be noted that most evidence that 
supports this function was obtained using reconstituted systems 
in vitro. These are prone to artifacts, and thus, more physiologi-
cal data from endogenous NLRC5 should be used to establish a 
working model for an eventual function of NLRC5 in the regula-
tion of inflammasomes.
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TYPe i inTeRFeROn ReSPOnSeS
Type I interferon responses are pivotal to control viral pathogens 
and contribute to immune defense in multiple pathways (36). 
Intriguingly, the first publication on NLRC5 by Kuenzle reported 
that NLRC5 is involved in the regulation of type I interferon 
responses (15). The authors show that human NLRC5 contains 
an IFNγ sensitive promoter and that NLRC5 mRNA is induced 
in several human cell lines and primary dermal fibroblasts by 
IFNγ treatment or cytomegalovirus (CMV) infection. Their work 
further revealed that NLRC5 might be able to target ISRE and 
gamma-activated sequence (GAS) promotor elements, although 
this finding was not confirmed by others (16). Finally, siRNA-
mediated knockdown of NLRC5 led to reduced type I interferon 
responses toward CMV infection in HeLaS3 cells and primary 
human dermal fibroblasts (15). Similar results on the induction of 
NLRC5 expression and function were reported by Neerincx et al. 
using Sendai virus infection and poly(I:C) stimulation of human 
cell lines and primary human dermal fibroblasts (16).
Virus-induced induction of NLRC5 mRNA by respiratory 
syncytial virus and influenza A virus was subsequently shown to 
be dependent on the antiviral PRR retinoic acid-inducible gene I 
(RIG-I) (37, 38). This is mediated by an autocrine loop involving 
the signal transducer and activator of transcription 1 (STAT1) 
interferon pathway, elegantly shown by genetic depletion of 
STAT1 and IFNAR1 in mice (10, 29).
In vitro infection studies using human airway epithelial cells 
suggest a biological role of NLRC5 in antiviral immunity toward 
influenza A virus (PR8). Influenza virus replication was shown 
to be impaired by NLRC5 expression in human airway epithelial 
cells and type I interferon responses of a NS1 deletion strain were 
found to be partly dependent on NLRC5 in a RIG-I-dependent 
manner (38). Accordingly, overexpression of the NLRC5 homolog 
in zebrafish was shown to repress spring viremia of carp virus 
replication in fish cells and embryos (39). Several reports indicate 
that this function is mediated by physical interaction of NLRC5 
with RIG-I (14, 38) and melanoma differentiation-associated 
protein 5 (MDA5) (14) and the signaling kinase TANK-binding 
kinase 1 (TBK1) (27). Accordingly, several groups reported that 
overexpression of NLRC5 in human embryonic kidney cells 
(HEK293T) results in reduced IFNγ-gene reporter activation 
upon triggering of the IFN pathway by TBK1 overexpression 
(14, 16, 27). Still, caution needs to be taken when interpreting 
the effects of NLR protein overexpression in gene reporter assays 
as these might lead to titration of co-actors and are prone to 
posttranslational effects, resulting in non-physiological effects 
(40). Knockdown and genetic ablation studies are more suited to 
avoid such shortcomings, although harbor pitfalls on their own. 
Surprisingly, the effect of siRNA-mediated knockdown of NLRC5 
is opposing in reports from different groups (14–16). Consistent 
with the gene reporter assays, Cui et al. found that NLRC5 knock-
down resulted in higher IFNβ responses upon poly(I:C) and 
vesicular stomatitis virus (VSV) treatment of human and murine 
monocytes (14). In a follow-up study, the same authors showed 
that NLRC5-deficient MEFs also have higher type I interferon 
responses upon VSV infection and confirmed in vivo that Nlrc5−/− 
mice have lower VSV titers and higher type I interferons (29). It 
should be noted that the mice used for this study were generated 
by targeting exon 8 of NLRC5, leaving the possibility that these 
animals still expressed a NLRC5 truncation protein without LRRs 
(29). This might be of a concern, as a NLRC5 construct lacking 
the LRRs is still able to repress influenza virus replication and 
responses (38). Indeed, an independent Nlrc5−/− mouse line, in 
which exon 4 was targeted, did not reveal any effect of NLRC5 
on type I interferon responses, although this work was restricted 
to particular cell types, mainly GM-CSF-induced bone marrow 
dendritic cells (27).
Taken together, the in vitro data strongly suggest that NLRC5 
can contribute to antiviral type I interferon responses in the cyto-
sol via interaction with Rig-I, MDA5, and TBK1 (14, 27, 38) and 
possibly by direct targeting of ISRE and interferon-GAS promotor 
elements (15) (Figure 2C). The discrepancies between positive and 
negative effects and lack of contribution of NLRC5 to interferon 
responses in certain settings await careful assessment, leaving the 
biological role of NLRC5 in type I interferon responses elusive at 
present. Independent replication of these studies and controlled 
back-to-back comparison of the effect of NLRC5 depletion in dif-
ferent cell types and species will help to reveal the potential role of 
NLRC5 in type I interferon responses in the future.
MALiGnAnT TRAnSFORMATiOn AnD 
CeLL CYCLe
Very recently, several reports from one lab showed that NLRC5 
has a role in liver pathologies in hepatic fibrosis. NLRC5 is highly 
expressed in fibrotic liver tissue in mice and decreased expres-
sion was observed during resolution (41). Accordingly, NLRC5 
mRNA expression is high in primary hepatocellular carcinoma 
(HCC) tissue and in cell lines such as HepG2, SMMC-7721, and 
BEL-7402 (42). In LX-2 hepatic stellate cells, TNF was shown 
to induce the expression of NLRC5 and NLRC5 can positively 
affect the expression of NF-κB target cytokines in these cells, 
likely involving Smad3 activation (43). In human keloid, a 
fibrotic tumor, characterized by extensive ECM deposition and 
hyperproliferation of fibroblasts in the skin, NLRC5 is also highly 
expressed. It was shown that in this tumor entity, NLRC5 knock-
down suppressed cell proliferation and ECM deposition, involv-
ing transforming growth factor beta 1 (TGF-β1) and Smad2/3 
(44). This suggests that NLRC5 might be able to interfere with 
Smad signaling in different malignant transformation processes.
Knockdown of NLRC5 in HepG2, SMMC-7721, and BEL-7402 
cells resulted in somewhat lower cell proliferation rates and silenc-
ing of NLRC5 lead to G1 cell cycle arrest (42). Another study con-
firmed a correlation of NLRC5 expression and cell proliferation 
in HCC and suggested that NLRC5 modulates cell proliferation 
and the expression of VEGF-A in an AKT-dependent manner 
(45). There are also data available that link NLRC5 expression 
to cell migration and invasion, the most important features of 
malignant cell behavior. The authors show that NLRC5-induced 
activation of Wnt/catenin signaling pathway and subsequent 
expression of the Wnt target genes c-myc, cyclinD1, and MMP-7 
might be causal for these effects (42), although these results await 
independent confirmation and validation in vivo.
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To conclude, these reports suggest that NLRC5 might con-
tribute to malignant transformation in multiple ways and in a 
tissue-dependent manner, likely by directly interfering with cell 
proliferation pathways (Figure 2D). Surprisingly, these results 
are opposing the established negative correlation of NLRC5 
expression and tumor immunogenicity mediated by MHC class 
I-dependent antigen presentation and CTL-mediated restriction 
of malignant cells [reviewed in Ref. (46)]. Further research will 
provide more detailed analysis in different tumor entities and 
in  vivo relevance to establish an eventual role and molecular 
function of NLRC5 in cell proliferation and cell signaling 
pathways.
COnCLUSiOn
The function of many mammalian NLR proteins still is enig-
matic. The identification of NLRC5 as the major MHC class 
I regulator added a lot to our understanding of the principles 
of immunology. However, many open questions regarding the 
biological function of this molecule remain to be answered. 
Both CIITA and NLRC5 are complex, high molecular weight 
proteins composed of highly structured domains that presum-
ably require high energy consumption for folding and synthesis. 
In an evolutionary perspective, it is hard to imagine how such 
complex proteins remained conserved to function “only” as 
transcriptional activators. The involvement of many mammalian 
NLR proteins and their counterparts in autonomous immunity 
in plants also suggest additional functions. Notably, in plants, 
some NLR proteins function as sensors for pathogen invasion 
and mediate triggering of transcriptional activation in ways 
that are very similar to the function of CIITA and NLRC5 (2). 
Currently, it is unclear if NLRC5, and eventually CIITA, might 
function as PRRs or might have lost such functionality. For 
CIITA, no MHC II-independent function has been reported 
so far. The accumulating evidence discussed above, however, 
argues that NLRC5 at least takes part in the fine regulation of 
innate immune pathways. Structural information on NLRC5 and 
CIITA would help to get further insights into these functions. 
Unfortunately, NLR proteins are intrinsically difficult to express, 
likely a reason why most NLRs, including NLRC5, are expressed 
endogenously at very low levels.
In contrast to CIITA and the other NLRs, NLRC5 con-
tains an unusual N-terminal domain, which shows some 
similarity to CARD domains (16, 25). This domain has intrinsic 
transcription activity and can transfer MHC II promotor activa-
tion when fused to CIITA (22). Future work revealing proteins 
that interact with this domain might provide insights into the 
function of this domain.
Given the well-established function of NLRC5 in MHC class I 
gene regulation, we also should be open minded to consider that 
changes in the expression of MHC I genes might be causal for, 
or at least contribute to the above discussed effects of NLRC5 on 
inflammatory responses. As it was shown that constitutive MHC 
I molecules can negatively affect the outcome of TLR stimulation 
in myeloid cells (47), it is conceivable that classical and eventually 
also the non-classical MHC molecules shape the outcome if innate 
immune responses more importantly as previously recognized.
At this time, it is very hard to draw a definite conclusion on 
the role of NLRC5 in innate immune responses. In particular, the 
mild phenotypes call for very careful and sophisticated analysis, 
which unfortunately often is not provided in the cited studies. It 
also should be reminded that NLRC5 is highest expressed in T 
cells in both human and mice (7, 10, 13, 15, 16), although nearly 
all cited work discussed above was conducted in myeloid and epi-
thelial cells. Work in tissue and cells with higher basal expression of 
NLRC5 might help to yield more robust and physiological relevant 
data. Moreover, uncertainties about the genetic background of 
the different mouse strains used, off-target effects of siRNA and 
shRNA, and specificity of the used antibodies remain to be solved. 
Given that the NLRC5 field is only emerging, we are confident that 
applying improved technologies, such as CRISPR-Cas9, and pro-
gress in the recombinant expression of NLR proteins will lead to a 
better understanding of the biology of NLRC5 in the near future.
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